PE20050665A1 - ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL - Google Patents

ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL

Info

Publication number
PE20050665A1
PE20050665A1 PE2004001154A PE2004001154A PE20050665A1 PE 20050665 A1 PE20050665 A1 PE 20050665A1 PE 2004001154 A PE2004001154 A PE 2004001154A PE 2004001154 A PE2004001154 A PE 2004001154A PE 20050665 A1 PE20050665 A1 PE 20050665A1
Authority
PE
Peru
Prior art keywords
estra
trien
diol
vinyl
fluor
Prior art date
Application number
PE2004001154A
Other languages
English (en)
Inventor
Karl-Heinrich Fritzemeier
Christa Hegele-Hartung
Ludwig Neyses
Olaf Peters
Theo Pelzer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20050665A1 publication Critical patent/PE20050665A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDA AL USO DE AGONISTAS DE ERB 8 B-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17B-DIOL Y 17B-FLUOR-9A-VINIL-ESTRA-1,3,5(10)-TRIEN-3,16A-DIOL PARA PRODUCIR MEDICAMENTOS PARA LA PREVENCION Y/O TRATAMIENTO DE ENFERMEDADES CARDIACAS HIPERTENSIVAS, HIPERTENSION RELACIONADA CON EL EMBARAZO, DEFICIENCIA CARDIACA, ENTRE OTRAS
PE2004001154A 2003-11-26 2004-11-25 ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL PE20050665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090406 2003-11-26

Publications (1)

Publication Number Publication Date
PE20050665A1 true PE20050665A1 (es) 2005-11-02

Family

ID=34626396

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001154A PE20050665A1 (es) 2003-11-26 2004-11-25 ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL

Country Status (16)

Country Link
US (1) US20050148560A1 (es)
EP (1) EP1689410B1 (es)
JP (1) JP2007512279A (es)
AR (1) AR046672A1 (es)
AT (1) ATE395919T1 (es)
DE (1) DE602004014020D1 (es)
DK (1) DK1689410T3 (es)
ES (1) ES2307064T3 (es)
GT (1) GT200400241A (es)
PA (1) PA8618401A1 (es)
PE (1) PE20050665A1 (es)
PL (1) PL1689410T3 (es)
PT (1) PT1689410E (es)
TW (1) TW200530263A (es)
UY (1) UY28630A1 (es)
WO (1) WO2005051401A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CN101641013B (zh) 2007-01-22 2014-07-30 Gtx公司 核受体结合剂
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
HUP0300335A2 (hu) * 2000-04-12 2003-07-28 Schering Ag. 8béta-hidrokarbil-szubsztituált ösztratriének mint szelektív hatású ösztrogének, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US7414043B2 (en) * 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
WO2005051401A3 (en) 2005-09-01
PL1689410T3 (pl) 2008-10-31
EP1689410A2 (en) 2006-08-16
UY28630A1 (es) 2005-06-30
GT200400241A (es) 2005-10-31
PT1689410E (pt) 2008-08-18
US20050148560A1 (en) 2005-07-07
DE602004014020D1 (de) 2008-07-03
AR046672A1 (es) 2005-12-14
TW200530263A (en) 2005-09-16
DK1689410T3 (da) 2008-09-08
EP1689410B1 (en) 2008-05-21
WO2005051401A2 (en) 2005-06-09
ES2307064T3 (es) 2008-11-16
JP2007512279A (ja) 2007-05-17
PA8618401A1 (es) 2005-08-04
ATE395919T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
UY27720A1 (es) Aroilpiridinonas monocíclicas,
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
DE69739856D1 (de) Agonisten für den rezeptor des hepatozyten-wachstumsfaktors und deren anwendungen
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
TW200612919A (en) Lonidamine analogues and their use in male contraception and cancer treatment
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MXPA05005296A (es) Bis-aril sulfonamidas.
DE60330181D1 (de) Actriib-fusionspolypeptide und verwendungen dafür
ECSP055584A (es) Proceso para la preparación de fibrinógeno
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
CL2003002293A1 (es) Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular.
CR8167A (es) Procedimiento para la preparacion de derivados de espirobenzoacepina sustituida no peptidica
UY27203A1 (es) Bencimidazoles útiles en el tratamiento de la disfunción sexual
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
DE60327710D1 (de) Modifizierte zytokine für krebs therapie
PE20020511A1 (es) Uso de antiprogestinas para la induccion de apoptosis en una celula

Legal Events

Date Code Title Description
FC Refusal